NYU Langone Health and Dana-Farber Cancer Institute announced on July 30 a strategic collaboration to co-develop Solavia Decision Suite, a next-generation oncology support platform aimed at improving cancer care for both patients and clinicians. The partnership brings together NYU Langone's information technology capabilities with Dana-Farber's clinical expertise in oncology pathways to build a decision tool that supports precise, evidence-based, and standardized care delivery.
Solavia was launched internally at NYU Langone on June 30 and is now commercially available. The application integrates directly into the electronic health record, providing physicians with access to the latest evidence, biomarkers, guidelines, and therapeutic options. This approach is intended to help clinicians stay current in the fast-changing field of oncology while supporting impactful research.
John P. Leonard, MD, division chief of hematology and medical oncology and chief clinical officer at NYU Langone's Perlmutter Cancer Center, said, "As oncologists, we know that cancer therapy evolves quickly, and keeping clinicians current on the latest evidence relevant to each patient can save time and support the best possible care. Solavia is an exciting step toward making that expertise more accessible in real time and helping care teams navigate complex treatment decisions."
The initiative also aligns with broader goals in precision medicine and digital innovation at both institutions. By first implementing Solavia within its own health system before expanding adoption elsewhere, NYU Langone aims to ensure practicality and effectiveness in real-world settings. Any future proceeds from licensing will be reinvested into improvements for Solavia.
David Jackman, MD, medical director of clinical pathways and new business initiatives at Dana-Farber, said, "Solavia is designed with clinicians in mind and patients at the center. The platform is intended to support care teams with evidence-based, context-aware guidance that helps make cancer treatment more personalized, coordinated, and consistent." Commercialization efforts will be led by NYU Langone's Technology Opportunities and Ventures.
